Literature DB >> 27789731

Evaluation of Akt and RICTOR Expression Levels in Astrocytomas of All Grades.

Arthur William Alvarenga1, Luis Eduardo Machado1, Bruna Roz Rodrigues1, Fernanda Cristina Sulla Lupinacci1, Paulo Sanemastu2, Eduardo Matta1, Martín Roffé1, Luís Fernando Bleggi Torres3, Isabela Werneck da Cunha4, Vilma Regina Martins1, Glaucia Noeli Maroso Hajj1.   

Abstract

The mammalian target of rapamycin (mTOR) binds to several protein partners and forms two complexes, termed mTOR complexes 1 and 2 (mTORC1/2), that differ in components, substrates, and regulation. mTORC2 contains the protein Rapamycin-insensitive companion of mTOR (RICTOR); phosphorylates kinases of the AGC family, such as Akt; and controls the cytoskeleton. Even though the regulation of mTORC2 activity remains poorly understood, the hyperactivation of this signaling pathway has been shown to contribute to the oncogenic properties of gliomas in experimental models. In this work, we evaluated expression and phosphorylation of Akt, and expression of RICTOR and Ki-67 in 195 human astrocytomas of different grades (38 cases of grade I, 49 grade II, 15 grade III, and 93 grade IV) and 30 normal brains. Expression and phosphorylation of Akt increased with histological grade and correlated with a worse overall survival in glioblastomas (GBMs). RICTOR was overexpressed in grade I and II astrocytomas and demonstrated a shift to nuclear localization in GBMs. Nuclear RICTOR was associated to increased proliferation in GBMs. Our results point to an increase in total and phosphorylated Akt in high-grade gliomas and to a possible role of RICTOR in proliferations of high-grade GBM cells.

Entities:  

Keywords:  Akt; RICTOR; astrocytoma; mTOR

Mesh:

Substances:

Year:  2016        PMID: 27789731      PMCID: PMC5256195          DOI: 10.1369/0022155416675850

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  42 in total

Review 1.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

2.  A comparison between manual and automated evaluations of tissue microarray patterns of protein expression.

Authors:  Arthur W Alvarenga; Claudia M Coutinho-Camillo; Bruna R Rodrigues; Rafael M Rocha; Luiz Fernando B Torres; Vilma R Martins; Isabela W da Cunha; Glaucia N M Hajj
Journal:  J Histochem Cytochem       Date:  2013-01-21       Impact factor: 2.479

3.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

Authors:  Evanthia Galanis; Jan C Buckner; Matthew J Maurer; Jeffrey I Kreisberg; Karla Ballman; J Boni; Josep M Peralba; Robert B Jenkins; Shaker R Dakhil; Roscoe F Morton; Kurt A Jaeckle; Bernd W Scheithauer; Janet Dancey; Manuel Hidalgo; Daniel J Walsh
Journal:  J Clin Oncol       Date:  2005-07-05       Impact factor: 44.544

4.  mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma.

Authors:  Laura Annovazzi; Marta Mellai; Valentina Caldera; Guido Valente; Luciana Tessitore; Davide Schiffer
Journal:  Anticancer Res       Date:  2009-08       Impact factor: 2.480

5.  Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.

Authors:  Penelope Korkolopoulou; Georgia Levidou; Elias A El-Habr; Christina Piperi; Christos Adamopoulos; Vassilis Samaras; Efstathios Boviatsis; Irene Thymara; Eleni-Andriana Trigka; Stratigoula Sakellariou; Nikolaos Kavantzas; Efstratios Patsouris; Angelica A Saetta
Journal:  Histopathology       Date:  2012-06-13       Impact factor: 5.087

6.  PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.

Authors:  Sabine Mueller; Joanna Phillips; Arzu Onar-Thomas; Eloy Romero; Shichun Zheng; John K Wiencke; Sean M McBride; Cynthia Cowdrey; Michael D Prados; William A Weiss; Mitchel S Berger; Nalin Gupta; Daphne A Haas-Kogan
Journal:  Neuro Oncol       Date:  2012-06-29       Impact factor: 12.300

Review 7.  Targeting the PI3K signaling pathway in cancer.

Authors:  Kwok-Kin Wong; Jeffrey A Engelman; Lewis C Cantley
Journal:  Curr Opin Genet Dev       Date:  2009-12-16       Impact factor: 5.578

8.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

Authors:  Arnab Chakravarti; Gary Zhai; Yoshiyuki Suzuki; Sormeh Sarkesh; Peter M Black; Alona Muzikansky; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

9.  Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas.

Authors:  Halldora K Thorarinsdottir; Mariarita Santi; Robert McCarter; Elisabeth J Rushing; Robert Cornelison; Alessandra Jales; Tobey J MacDonald
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

Review 10.  mTOR signaling in glioblastoma: lessons learned from bench to bedside.

Authors:  David Akhavan; Timothy F Cloughesy; Paul S Mischel
Journal:  Neuro Oncol       Date:  2010-05-14       Impact factor: 12.300

View more
  9 in total

1.  Overexpression of mTOR and p(240-244)S6 in IDH1 Wild-Type Human Glioblastomas Is Predictive of Low Survival.

Authors:  Luis Eduardo Machado; Arthur William Alvarenga; Fernanda Ferreira da Silva; Martín Roffé; Maria Dirlei Begnami; Luís Fernando Bleggi Torres; Isabela Werneck da Cunha; Vilma Regina Martins; Glaucia Noeli Maroso Hajj
Journal:  J Histochem Cytochem       Date:  2018-01-12       Impact factor: 2.479

Review 2.  The role of metabolic ecosystem in cancer progression - metabolic plasticity and mTOR hyperactivity in tumor tissues.

Authors:  Anna Sebestyén; Titanilla Dankó; Dániel Sztankovics; Dorottya Moldvai; Regina Raffay; Catherine Cervi; Ildikó Krencz; Viktória Zsiros; András Jeney; Gábor Petővári
Journal:  Cancer Metastasis Rev       Date:  2022-01-14       Impact factor: 9.264

3.  Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.

Authors:  Sejin Oh; Jeonghun Yeom; Hee Jin Cho; Ju-Hwa Kim; Seon-Jin Yoon; Hakhyun Kim; Jason K Sa; Shinyeong Ju; Hwanho Lee; Myung Joon Oh; Wonyeop Lee; Yumi Kwon; Honglan Li; Seunghyuk Choi; Jang Hee Han; Jong Hee Chang; Eunsuk Choi; Jayeon Kim; Nam-Gu Her; Se Hoon Kim; Seok-Gu Kang; Eunok Paek; Do-Hyun Nam; Cheolju Lee; Hyun Seok Kim
Journal:  Nat Commun       Date:  2020-07-03       Impact factor: 14.919

4.  Aberrant expression of RSK1 characterizes high-grade gliomas with immune infiltration.

Authors:  Glaucia N M Hajj; Fernanda F da Silva; Bárbara de Bellis; Fernanda C S Lupinacci; Hermano M Bellato; Juvanier R Cruz; Claudionor N C Segundo; Igor V Faquini; Leuridan C Torres; Paulo I Sanematsu; Maria D Begnami; Vilma R Martins; Martín Roffé
Journal:  Mol Oncol       Date:  2019-12-11       Impact factor: 6.603

5.  An Immunohistochemical Study of the PTEN/AKT Pathway Involvement in Canine and Feline Mammary Tumors.

Authors:  Pietro Asproni; Francesca Millanta; Lorenzo Ressel; Fabio Podestà; Francesca Parisi; Iacopo Vannozzi; Alessandro Poli
Journal:  Animals (Basel)       Date:  2021-02-01       Impact factor: 2.752

Review 6.  Dodging the bullet: therapeutic resistance mechanisms in pediatric cancers.

Authors:  Nilay Shah
Journal:  Cancer Drug Resist       Date:  2019-09-19

7.  PP242 Counteracts Glioblastoma Cell Proliferation, Migration, Invasiveness and Stemness Properties by Inhibiting mTORC2/AKT.

Authors:  Carmen Mecca; Ileana Giambanco; Stefano Bruscoli; Oxana Bereshchenko; Bernard Fioretti; Carlo Riccardi; Rosario Donato; Cataldo Arcuri
Journal:  Front Cell Neurosci       Date:  2018-04-10       Impact factor: 5.505

8.  Xihuang Pill Induces Apoptosis of Human Glioblastoma U-87 MG Cells via Targeting ROS-Mediated Akt/mTOR/FOXO1 Pathway.

Authors:  Meng Shao; Zhenqiang He; Zhixin Yin; Peihong Ma; Qian Xiao; Yafeng Song; Ziming Huang; Yujie Ma; Yuqin Qiu; Aizhi Zhao; Taicheng Zhou; Qirui Wang
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-26       Impact factor: 2.629

9.  Polysome Profiling of a Human Glioblastoma Reveals Intratumoral Heterogeneity.

Authors:  Fernanda Cristina Sulla Lupinacci; Hellen Kuasne; Martin Roffé; Julia Avian Vassalakis; Fernanda Ferreira da Silva; Tiago Góss Santos; Victor Piana Andrade; Paulo Sanematsu; Vilma Regina Martins; Silvia Regina Rogatto; Glaucia Noeli Maroso Hajj
Journal:  Int J Mol Sci       Date:  2019-05-02       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.